This website is Your privacy and the protection of your data is important to Cerevance, LLC and its subsidiary entities (“Cerevance”, “us” or “we”) and we recognize the responsibility you entrust in us when providing your personal information. This Privacy Policy explains how we handle and treat your data when you visit our website and engage with us, as further described below. The purpose of this Privacy Policy is to provide you with a clear explanation of what personal data we collect, and when, why, and how we collect, use, or share your personal data. It also explains your legal rights regarding such data.
We strongly urge you to read this Privacy Policy and make sure you fully understand our practices in relation to personal data before you utilize our website. After you have read this notice, if you would like further information or have any questions, you may contact us at info@cerevance.com.
(If you are located in the European Economic Area (EEA), in addition to this Privacy Policy, please consult the EEA GDPR supplemental notice below.)
owned and operated by Cerevance, LLC, a limited liability company with a business address of One Marina Park Drive, Suite 1410, Boston, MA 02210, United States, and its subsidiaries(collectively “Cerevance”, “we”, or “us”).
These Terms of Use refer to the current website you are visiting (the “Website”). All access to and use of this Website is governed by these Terms of Use. Visiting and using this Website indicates that the user (either “user” or “you” in this document) has reviewed these Terms of Use and has agreed to be bound by them as well as our Privacy Policy. The information provided on our Website is for informational purposes only. If you do not agree to these Cerevance Terms ofUse and Privacy Policy, you may not use or access this Website and are requested to leave the Website immediately.
Cerevance’s company mission is to alleviate and eradicate diseases of the central nervous system through robust clinical research and solutions, with several promising products currently undergoing clinical trials. To provide prospective patients and other interested parties with helpful information and a beneficial experience overall when visiting the Cerevance website, Cerevance may collect certain types of personal data from visitors.
This Privacy Policy applies to data received or collected through this Cerevance website, as well as from platforms and other sources related to or initiated by this website.
ALL MATERIALS POSTED ON THIS WEBSITE ARE PROVIDED “AS IS” AND WITHOUT WARRANTIES EXPRESS OR IMPLIED. CEREVANCE AND ITS AGENTS AND THE WEBSITE CREATORS DISCLAIM TO THE FULLEST EXTENT PERMISSIBLE BY APPLICABLE LAW, ALL WARRANTIES INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. CEREVANCE DOES NOT WARRANT THAT FUNCTIONS CONTAINED ON THIS WEBSITE WILL BE UNINTERRUPTED OR ERROR-FREE, THAT DEFECTS WILL OR CAN BE CORRECTED, OR THAT THIS WEBSITE OR THE SERVER ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. CEREVANCE DOES NOT PROVIDE ANY WARRANTY OR REPRESENTATION AS TO THE MATERIALS ON THIS WEBSITE IN TERMS OF THEIR CORRECTNESS, ACCURACY, RELIABILITY, OR OTHERWISE.
As mentioned above, Cerevance may collect information about you including, if you voluntary provide it, personal data that can be used to identify you personally, such as your name, date of birth, home address, phone number, e-mail address, or certain personal health information.
(For website visitors in the EEA, subject to rights for opting in or opting out of sharing data where and when applicable, this information may include sensitive personal data, such as your historical health information and other related information, to the extent you voluntary provide such data.)
With your consent, we may use your personal data to:
We may share your personal data with other parties as described in this Privacy Policy, including following categories of third parties:
Affiliates: We may share your personal data with our corporate parent, subsidiaries, and affiliates.
Business partners / services providers: We may share your personal data with our business partners / service providers as necessary for them to provide services to us in connection with our fulfilment of the purposes set out above. For example, we may rely on service providers to: host our server and software; distribute Cerevance information updates; provide responses and answers to inquiries; etc. Some of these third parties include Microsoft, Psynthesys, Inc., as well as other parties we may work with from time to time.
Government Agencies, Regulators and Professional Advisors: Where permitted or required by applicable law or regulation, we may also need to transfer your personal data to government agencies and regulators (such as drug regulators, tax authorities, courts, and other government authorities) to comply with our legal obligations, and to external professional advisors as necessary to defend our legal interests.
Organizations Involved in Business Transfers: In the event of a merger, reorganization, dissolution or similar corporate event, or the sale of all or substantially all of our assets, we expect that the information that we have collected, including personal data, will be transferred to the acquiring entity or the surviving entity in a merger or other such transaction. Such information would be transferred in accordance with applicable law.
In certain cases, we may redact or delete information from your personal information to make it non-identifiable, or tabulate/combine de-identified information into aggregated form. We may use such de-identified or aggregated data (which cannot be used to identify you) for all legitimate business purposes, such as business operations, product research, marketing, and strategy.
We may also share de-identified or aggregated information about our visitors with outside parties, such as our business partners, affiliates, national associations, or appropriately contracted parties. As referenced above, such de-identified or aggregate information does not consist of personal or identifiable information (i.e., it does not constitute “Protected Health Information” (PHI) under HIPAA, or personal data under GDPR).
We are committed to keeping all personal data provided to us protected and secure, and we have implemented appropriate information security policies, rules and technical measures to protect personal data that we have under our control from unauthorized access, improper use or disclosure, unauthorized modification, and unlawful destruction or accidental loss. We have put in place procedures to deal with any suspected breach of personal data and will notify individuals and any applicable regulator of a breach where we are legally required to do so.
We retain personal data for as long as necessary to fulfil the purposes for which we collected it, including for purposes of satisfying any legal, accounting, regulatory, monitoring, or reporting requirements, to establish or defend legal claims, or for fraud prevention purposes. When we no longer require the personal data we have collected about you, we will either delete or irreversibly anonymize it or, if this is not possible (for example because your personal data has been stored in backup archives), then we will securely store your personal data and isolate it from any further processing until deletion is possible. If we anonymize your personal data (so that it can no longer be associated with you), we may use this information indefinitely without further notice to you.
As the data owner, you will maintain control over your data as governed by applicable laws and regulations. To the extent you would like to make changes to your personal data that is maintained by Cerevance, you may contact Cerevance with an explanation of corrections or limitations to place on your personal data. For your protection, we may only implement requests with respect to the personal data associated with the particular email address that you used to send us your request, and we may contact you or take other steps to verify your identity before implementing your request. Please note that we may not be able to accommodate every request for a change, correction, or limitation, and we may need to retain certain information for record-keeping, regulatory or legal purposes, and/or to complete any communications that you began prior to requesting any change.
(For EEA residents, please review the EEA GDPR Supplemental Notice below.)
We are headquartered in the United States with business locations and service providers in other countries. Based on the specific circumstances, your personal data may cross borders and be transferred to the United States or other locations outside of your country where privacy laws may not be as protective as those in your country. We will take appropriate steps to ensure that transfers of personal data are in accordance with applicable laws (including providing notice and obtaining consent, as necessary).
(For EEA residents, please review the EEA GDPR Supplemental Notice below.)
Cerevance does not knowingly collect any personal data from persons under 18. If we learn that we have collected or received personal data from any person under 18 without verification of parental consent, we will delete that information.
Our website, from time to time, may contain links to and from the websites of our partner organizations, networks, advertisers or affiliates. If you follow a link to any of these websites, please note that these websites have their own privacy policies and we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.
You may contact us by sending a message to: info@cerevance.com. You may also mail us a message or inquiry at the following address:
Cerevance, Inc.
One Marina Park Drive, Suite 1410
Boston, MA 02210 USA
Attention: Data Privacy Official
We may make changes to this Privacy Policy. To ensure that you are always aware of how we use your personal data, we will update this Privacy Policy from time to time to reflect any changes to our use of personal data. We may also make changes as required to comply with changes in applicable law or regulatory requirements and emerging privacy practices. Please regularly check this document or this webpage for the latest version of this Privacy Policy.
If you are located in the European Economic Area or the United Kingdom and have provided your personal data to Cerevance through this website or otherwise, this EEA GDPR Supplemental Notice applies to you.
For questions about our Privacy Policy in the EEA, exercising your privacy rights, or to lodge a complaint in the EEA, please contact us via our Data Privacy Representative (DPR), DPO Consultancy, at dpr@dpoconsultancy.nl or send mail to the following address:
Europalaan 28b
5232 BC - ‘s-Hertogenbosch
the Netherlands
Cerevance, LLC, a company based in the United States, with a business address of One Marina Park Drive, Suite 1410, Boston, MA 02210, is considered the controller of your personal data.
Cerevance’s Data Protection Official can be contacted by e-mailing info@cerevance.com, or by writing to:
Cerevance, Inc.
One Marina Park Drive, Suite 1410
Boston, MA 02210 USA
Attention: Data Privacy Official
The purpose and legal grounds for data processing activities may include one or more of the following:
Provision of Information & customer service
Website visitor engagement and services improvement
Marketing
Internal business purposes
Compliance with our regulatory and legal obligations
We welcome submissions to this Website in the form of questions, requests, user information, and other. If you submit information to Cerevance through this Website (e.g., the “Contact Us” webpage, via email, forms and/or questionnaires), all such information may be processed and utilized by Cerevance in accordance with the Privacy Policy and consistent with applicable laws and regulations. Cerevance shall have all appropriate use for the information without compensation to the user or visitor who provided the information. You agree that you are responsible for all submissions that you provide and you, not Cerevance, shall have full responsibility of their
You have the following rights in relation to your personal data, in accordance with GDPR requirements and applicability to Cerevance as a data processor:
Right of access: You can ask us Cerevance to provide you with information about our processing of your personal data and provide reasonable access to your personal data.
Right to rectification: If the personal data we have about you is inaccurate or incomplete, you are entitled to request to have it rectified.
Right to erasure: You can ask us to delete or remove personal data where there is no lawful reason for us continuing to store or process it, where you have successfully exercised your right to object to processing (see below), where we may have processed your information unlawfully, or where we are required to erase your personal data to comply with local law. Note, however, that we may not always be able to comply with your request of erasure for specific legal reasons that will be notified to you, if applicable, at the time of your request.
Right to restrict processing: You can ask us to suspend the processing of your personal data if: (i) you want us to establish the data’s accuracy; (ii) where our use of the data is unlawful but you do not want us to erase it; (iii) where you need us to hold the data even if we no longer require it, as you need it to establish, exercise or defend legal claims; or (iv) you have objected to our use of your data but we need to verify whether we have overriding legitimate grounds to use it.
Right to object: Where we are relying on a legitimate interest for data processing but there is something about your particular situation, you have the right to object to processing if you believe it impacts on your fundamental rights and freedoms.
Right to data portability: You have the right in certain circumstances to ask us to provide you, or a third party you have chosen, with your personal data in a structured, commonly used, machine-readable format. Note that this right only applies to automated information for which you initially provided consent for Cerevance to use, or where we used the information to perform a contract with you.
Right to withdraw consent at any time: Where we are relying on consent to process your personal data, you have the right to withdraw your consent at any time. However, this will not affect the lawfulness of any processing conducted before you withdraw your consent.
Right to lodge a complaint with a supervisory authority: You may submit a complaint about our use of your personal data, or our response to your requests regarding your personal data. To do this, you may contact us or submit a complaint to the Supervisory Authority in your jurisdiction: https://edpb.europa.eu/about-edpb/about-edpb/members_en. Please note that some of these rights may be limited where we have an overriding interest or legal obligation to continue to process the personal data, or where certain exemptions apply. In order to exercise your rights, please contact Cerevance in writing by one of the methods set out under “Contact Us” above.
We may transfer your personal data to recipients outside of the EEA and/or UK. Some of these recipients are located in countries for which either the European Commission and/or UK Government (as and where applicable) has issued adequacy decisions, in which case, the recipient’s country is recognized as providing an adequate level of data protection under UK and/or European data protection laws, and the transfer is therefore permitted under Article 45 of the GDPR.
Some recipients of your personal data may be located in countries outside the EEA and/or the UK for which the European Commission or UK Government (as and where applicable) has not issued adequacy decisions in respect of the level of data protection in such countries (“Restricted Countries”). For example, the United States is a Restricted Country. Where we transfer your personal data to a recipient in a Restricted Country, we will either:
Enter into appropriate data transfer agreements based on so-called Standard Contractual Clauses approved from time-to-time under GDPR Art. 46 by the European Commission, the UK Information Commissioner’s Office or UK Government (as and where applicable); or
Rely on other appropriate means permitted by the EU/UK GDPR, which establish that such recipients will provide an adequate level of data protection and that appropriate technical and organizational security measures are in place to protect personal data against accidental or unlawful destruction, loss or alteration, unauthorized disclosure or access, and against all other unlawful forms of processing.
You may contact us in writing by one of the methods set out under the “Contact us” provision above, if you would like further information on the specific mechanism used for transferring your personal data outside of the EEA.
Current
December 5, 2025
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease
April 1, 2025
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
March 27, 2025
New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson’s Disease and Deep Pipeline for CNS-based Disorders
November 18, 2024
Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease
November 11, 2024
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
October 21, 2024
Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinical Medicine
Cerevance has published the full results from the Phase 2 clinical trial of solengepras, in eClinicalMedicine, a peer-reviewed journal published by The Lancet Discovery Science Suite. The results demonstrated that solengepras, a potentially first-in-class, oral, once-daily, non-dopaminergic, GPR6 inverse agonist, significantly reduced OFF time in individuals with Parkinson’s disease and was generally well-tolerated.
October 17, 2024
Sarah Sheikh Joins Cerevance’s Board of Directors
Cerevance is pleased to appoint Sarah Isabel Sheikh, M.Sc., B.M. B.Ch., MRCP, to its Board of Directors, effective immediately. Dr. Sheikh holds dual responsibilities at Takeda as the Head of Global Development for all therapeutic areas – Gastrointestinal and Inflammation, Neuroscience, Oncology, Plasma-Derived Therapies, and Vaccines – and as the Head of the Neuroscience Therapeutic Area.
October 8, 2024
Cerevance Achieves Second Milestone in Research Collaboration with Merck
Cerevance announced the achievement of the second milestone in its research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification and validation of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers a payment from Merck to Cerevance.
August 12, 2024
Cerevance Appoints Sagar Vaidya, M.D., Ph.D., as Chief Medical Officer
Cerevance has appointed Dr. Sagar Vaidya, M.D., Ph.D., as Chief Medical Officer. Dr. Vaidya brings a wealth of experience in drug development, clinical research, and medical affairs, with a distinguished track record in advancing therapeutic programs for severe and life-threatening diseases.
May 2, 2024
Cerevance Achieves First Milestone in Research Collaboration with Merck
Cerevance achieves first milestone in research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers an undisclosed payment from Merck to Cerevance.
April 25, 2024
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
Cerevance announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million.
April 22, 2024
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
Cerevance announces that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
February 15, 2024
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters. In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist”
November 13, 2023
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
September 19, 2023
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.
August 28, 2023
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.
July 10, 2023
Cerevance to Present at the Alzheimers Association International Conference
Cerevance to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.
May 16, 2023
Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
Cerevance to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.
May 9, 2023
Cerevance to Present at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia, Canada, May 15 – 19, 2023.
April 13, 2023
Poster Presentation at the BNA International Festival of Neuroscience
Cerevance today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023
March 21, 2023
Cerevance to Present at Two Medicinal Chemistry Conferences
Cerevance to present at two upcoming medicinal chemistry conferences:
March 20, 2023
Cerevance to Present at AD/PD™ 2023 International Conference
February 13, 2023
Cerevance Expands Series B Financing with Additional $51 Million
January 27, 2023
Cerevance Announces Publication in Organic Process Research and Development
Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.
January 9, 2023
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
November 30, 2022
Cerevance to Present Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
August 9, 2022
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
April 19, 2022
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
Cerevance today announced the appointment of Craig Thompson to chief executive officer. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.
March 31, 2022
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
Cerevance today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.
January 25, 2022
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
September 8, 2021
Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors
Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.
February 1, 2021
Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls
Cerevance today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
February 1, 2021
Cerevance Appoints Carrie Ann Cook as Chief Business Officer
Cerevance, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer
December 8, 2020
Cerevance Appoints David Lubner to Board of Directors
Cerevance today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors.
November 16, 2020
Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
Cerevance today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).
July 21, 2020
Cerevance Expands Series B Financing to $65 Million
Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April.
April 14, 2020
Cerevance Closes $45 Million Series B Financing
Cerevance has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors...
January 7, 2020
Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors
Dr. Brennan is currently president and chief executive officer of Synlogic, Inc. (Nasdaq:SYBX), a clinical stage biotechnology company applying synthetic biology to beneficial microbes to develop novel, living medicines.
December 17, 2019
Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders
Cerevance has formed a multi-year research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI disorders.
December 4, 2019
Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease
Cerevance, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel, non-dopaminergic target selectively expressed in an important class of neurons in the striatum.
June 3, 2019
Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor
Cerevance has appointed pharmaceutical industry veteran, James Summers, Ph.D., as a key scientific advisor to guide the company in its drug discovery and development efforts. Dr. Summers brings extensive experience in the discovery of...
April 30, 2019
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, orally-delivered compound in development for the treatment of Parkinson’s disease.
April 16, 2019
Cerevance Appoints Industry Veteran Roland Bürli, Ph.D. as Vice President of Drug Discovery
Roland Bürli, Ph.D. as Vice President of Drug Discovery brings expertise in preclinical drug discovery, specializing in medicinal and synthetic chemistry, with a proven track record from hit identification through lead optimization, having led efforts that discovered six pre-clinical candidate molecules, including a program now in Phase II.
March 5, 2019
Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience
Dawson brings 25 years of career experience spearheading drug discovery and development across companies based in the United States, Japan and the United Kingdom. Most recently, he served as Vice President of CNS drug development at Astex Pharmaceuticals, where he established and developed their global neuroscience research strategy.
October 9, 2018
Cerevance Appoints Ted Hibben as Chief Business Officer
A twenty-year biotechnology industry veteran, Mr. Hibben has formed over $2 billion in platform and product-based R&D collaborations. Prior to joining Cerevance, Mr. Hibben served as Chief Business Officer at Catabasis where he led partnering activities.
September 25, 2018
Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease
Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.
February 21, 2018
Cerevance Kicks Off 2018 with Additional $10 Million of Infusions
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has received an additional equity investment as well as a non-dilutive cash payment in the first six weeks of 2018 totaling more than $10 million.
November 27, 2017
Cerevance Appoints David H. Margolin, M.D., Ph.D., as Senior Vice President of Clinical and Translational Medicine
Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period. There, he leveraged his expertise in designing and leading translational medicine initiatives as well as clinical trials from phase 1 to phase 4 across various neurologic and rare disease indications...
October 24, 2017
Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, M.D., Ph.D., to Advise Cerevance
Dr. Nathans is Professor of Molecular Biology and Genetics, Neuroscience and Ophthalmology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, where his research focuses on molecular mechanisms of visual system development, function, and disease. He is also an Investigator in the Howard Hughes Medical Institute.
October 17, 2017
Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue
October 12, 2017
Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
Cerevance, a drug discovery and development company focused on brain diseases, today announced that Rudolph Tanzi, Ph.D., has joined the company as a senior-level scientific advisor.
October 5, 2017
Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., to Advise Cerevance
Cerevance, a drug discovery and development company, today announced that Robert Malenka, M.D., Ph.D., has joined the company as a senior-level scientific advisor. Dr. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences at Stanford University.
May 3, 2017
Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia
The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance.
December 2, 2016
Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
Current
December 1, 2025
Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
November 24, 2025
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
November 17, 2025
Cerevance to Participate in the TD Cowen Treatment Advancements in Obesity and Related Disorders Summit
September 22, 2025
Cerevance to Present Phase 2 Data on Solengepras in Parkinson’s Disease at the 2025 International Congress of Parkinson's Disease and Movement Disorders
August 7, 2025
Cerevance to Participate in Piper Sandler Virtual CNS Symposium
July 11, 2025
Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025
April 8, 2025
Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting
April 1, 2025
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
September 23, 2024
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
May 20, 2024
Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
May 9, 2024
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
April 29, 2024
Cerevance to Present at RBC Capital Markets 2024 Global Healthcare Conference
April 29, 2024
Cerevance to Participate at Wells Fargo Virtual Private Biotech Symposium
April 17, 2024
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
April 2, 2024
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
March 13, 2024
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
February 27, 2024
Cerevance Announces Presentation at AD/PD™ 2024 International Conference
February 22, 2024
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
December 5, 2023
Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference
November 28, 2023
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
November 7, 2023
Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting
November 1, 2023
Cerevance to Participate in the Truist Securities BioPharma Symposium
October 25, 2023
Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium
October 18, 2023
Cerevance to Participate at the Leerink Biopharma Private Company Connect
October 10, 2023
Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum. Company management will host one-on-one meetings during the conference.
October 4, 2023
Cerevance to Participate at the 2023 Life Sciences Private Company Showcase
October 2, 2023
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
September 5, 2023
Cerevance to Present During the 6th Annual LSX World Congress USA
August 31, 2023
22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium
July 10, 2023
Alzheimers Association International Conference
June 28, 2023
XVI European Meeting on Glial Cells in Health and Disease
June 26, 2023
Gordon Research Conference
May 16, 2023
Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
May 9, 2023
Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
May 8, 2023
2023 RBC Capital Markets Global Healthcare Conference
April 13, 2023
BNA International Festival of Neuroscience
April 10, 2023
Needham Healthcare Conference
March 27, 2023
Chief Medical Officer Summit 360˚
March 21, 2023
Two Medicinal Chemistry Conferences
March 20, 2023
AD/PD™ 2023 International Conference
March 7, 2023
Alzheimer’s Research UK Conference 2023
January 24, 2023
SVB Global Biopharma Conference
December 7, 2022
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
November 30, 2022
Biology and Therapeutics Conference
June 16, 2022
5th Annual LSX World Congress USA
June 8, 2022
2022 BIO International Convention
The ASCEND Parkinson’s Disease Clinical Research Study
The ASCEND clinical study is evaluating whether CVN424, an investigational drug, is safe and effective in improving the motor and non-motor symptoms of Parkinson’s disease.
